# US 2025/0144083 A1 · Methods and compositions for treating cancer in taxane-resistant patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144083 A1
- Document ID: US20250144083A1
- Status: Published application
- Kind: A1
- Application number: 18/838,206
- Filed: 2023-02-13
- Published: 2025-05-08
- Earliest claimed: 2022-02-14
- Assignees: Modra Pharmaceuticals B.V.
- Applicants: Modra Pharmaceuticals B.V.
- Inventors: Eric VAN DER PUTTEN; Colin FREUND
- Web page: https://patentgrep.com/patent/US20250144083A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions are provided for treating cancer in a taxane-resistant patient, comprising administering an effective dose of a taxane simultaneously or sequentially with a P-gp inhibitor, such as ritonavir or a pharmaceutically acceptable salt thereof. Also provided are methods and compositions for reversing taxane resistance in a patient, comprising administering an effective dose of a P-gp inhibitor, such as ritonavir or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method for treating cancer in a taxane-resistant patient, the method comprising administering an effective dose of a taxane simultaneously or sequentially with ritonavir or a pharmaceutically acceptable salt thereof.

### Claim 2

A method for reversing taxane resistance in a patient, comprising administering an effective dose of ritonavir or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein ritonavir, or a pharmaceutically acceptable salt thereof, is administered simultaneously or sequentially with an effective dose of a taxane.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the cancer comprises a solid tumour.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the cancer is selected from the group consisting of gastric cancer, breast cancer, head and neck cancer, lung cancer, and prostate cancer.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The method according to claim 5, further comprising determining if the cancer is responsive to treatment by determining the responsiveness of a DU-145 or 22Rv1 cell line to an effective dose of a taxane simultaneously or sequentially with ritonavir or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein ritonavir and/or a taxane is administered orally.

### Claim 9 (depends on 1)

The method according to claim 1, wherein ritonavir and/or a taxane is administered intravenously.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, pharmaceutically acceptable salts or esters thereof, and combinations thereof.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the taxane is docetaxel, or a pharmaceutically acceptable salt or ester thereof.

### Claim 12 (depends on 1)

The method according to claim 1, wherein ritonavir is administered at a weekly dose of about 50 mg to about 1200 mg.

### Claim 13 (depends on 1)

The method according to claim 1, wherein ritonavir is administered at a daily dose of about 50 mg to about 1200 mg.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the taxane is administered at a weekly dose of about 30 mg to about 500 mg.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the taxane is administered at a daily dose of about 0.1 mg to about 100 mg.

### Claim 16 (depends on 1)

The method according to claim 1, wherein ritonavir is administered at a daily dose of about 50 mg to about 1200 mg and the taxane is administered at a daily dose of about 0.1 mg to about 100 mg, wherein the daily doses of ritonavir and the taxane may be taken at the same or different time of day.

### Claim 17 (depends on 1)

The method according to claim 1, wherein ritonavir is administered at a weekly dose of about 50 mg to about 1200 mg and the taxane is administered at a weekly dose of about 30 mg to about 500 mg, wherein the weekly doses of ritonavir and the taxane may be taken on the same or different days.

### Claim at position 18

-53. (canceled)

### Claim 54

A kit comprising:
at least one pharmaceutical composition comprising a taxane; and
at least one pharmaceutical composition comprising a P-gp inhibitor.

### Claim 55 (depends on 54)

The kit of claim 54, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, pharmaceutically acceptable salts or esters thereof, and combinations thereof.

### Claim 56 (depends on 54)

The kit of claim 54, where the P-gp inhibitor is selected from the group consisting of ritonavir, elacridar and combinations thereof, or a pharmaceutically acceptable salt thereof.

### Claim 57

(canceled)

### Claim 58 (depends on 1)

The method according to claim 1, further comprising:
determining the expression of ABCB1 (P-gp) in the patient;
optionally, comparing the expression of ABCB1 (P-gp) to a reference level; and
optionally, determining a dosage of the ritonavir based on the expression level of ABCB1 (P-gp) determined in the subject.

### Claim at position 24

-60. (canceled)
